Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

September 2, 2021

Study Completion Date

September 2, 2021

Conditions
Migraine
Interventions
DRUG

"Treatment A: M207 3.8 mg MiniMac"

"Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups"

DRUG

"Treatment B: M207 3.8 mg MACAP"

"Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups"

DRUG

Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0

Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

All Listed Sponsors
lead

Zosano Pharma Corporation

INDUSTRY